A pooled analysis of all Evinacumab studies assessing the effect of the drug on lipoprotein(a) levels

High cholesterol is a major risk factor for heart disease, one of the leading causes of death worldwide. Some people have a genetic condition called familial hypercholesterolemia (FH), which leads to very high cholesterol levels and increases their risk of heart problems.

Evinacumab is a medication that has been studied for its ability to lower low-density lipoprotein (LDL) cholesterol, commonly known as "bad cholesterol." Early results from previous studies suggest that evinacumab may also reduce Lipoprotein(a), or Lp(a) levels, another type of cholesterol-carrying particle. However, these studies had small sample sizes and different dosage groups, making it difficult to determine whether evinacumab consistently lowers Lp(a) and which patients might benefit the most.

This study aims to combine data from all previous clinical trials of evinacumab to determine whether the drug effectively lowers Lp(a) levels. By analyzing a larger dataset, we hope to gain clearer insights into how evinacumab affects Lp(a) and identify which patients experience the most significant benefits. If successful, this research could reveal an additional advantage of evinacumab for patients with high Lp(a) levels and high LDL, potentially improving treatment options for those at increased risk of heart disease.

To conduct this research, we will use a method called a pooled analysis, which combines data from multiple previous studies. These studies included patients with different forms of high cholesterol, and those whose cholesterol remained high despite receiving the strongest available treatments. We will compare Lp(a) levels before and after treatment with evinacumab and assess whether the drug led to significant reductions compared to patients who did not receive it. Additionally, we will analyze whether patients with higher Lp(a) levels at the beginning of the studies experienced greater benefits.

By combining data from multiple trials, this study will help determine whether evinacumab can effectively lower Lp(a) levels. If confirmed, this could provide a new way to reduce the risk of heart disease for patients with high cholesterol, especially those who do not respond well to existing treatments. Our findings could contribute to better management of cholesterol-related health risks and improve patient outcomes.